false000172312800017231282026-05-062026-05-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 6, 2026
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3848593-4225266
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2026. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:

Proposal 1: To elect the following director nominees to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified:
 
 
For
 
 
Against
 
 
Abstain
 
 
Broker Non-Votes
 
Deb Autor
 
 
250,782,20820,907,57334,99221,948,638
 
J. Kevin Buchi
 
 
247,071,067



24,615,560


38,146



21,948,638
 
Jeff George


250,652,568



21,032,093


40,112



21,948,638

John Kiely
 
 
239,969,127



31,717,386


38,260



21,948,638
 
Paul Meister
 
 
237,733,309



33,950,919


40,545



21,948,638
 
Ted Nark
 
 
265,399,266


6,285,254


40,253



21,948,638
 
Chintu Patel
 
 
270,365,045



1,320,024


39,704



21,948,638
 
Chirag Patel
 
 
270,364,571



1,320,525


39,677



21,948,638
 
Gautam Patel
 
 
270,643,127



1,042,157


39,489



21,948,638
 
Shlomo Yanai
 
 
250,631,212



21,053,488


40,073



21,948,638


Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:
For
 
Against
 
Abstain
 
Broker Non-Votes
269,089,7852,577,48157,50721,948,638


Proposal 3: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
For
 
Against
 
Abstain
 
Broker Non-Votes
293,211,820

409,43552,156

0


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 7, 2026AMNEAL PHARMACEUTICALS, INC.
By:/s/ Jason B. Daly
Name:Jason B. Daly
Title:Executive Vice President and Chief Legal Officer and Corporate Secretary